MedTrace Logo

Control of Bleeding on Nexplanon in Latinx Patients

NCT05116371 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 144

Last updated 2021-11-11

No results posted yet for this study

Summary

In this study, researchers want to find out more about how the Etonogestrel (ENG) contraceptive implant device (also known as Nexplanon) changes people's periods. Study subjects will self select into an exposure group- starting combined hormonal contraceptive pills (COC) on the same day as Nexplanon placement or a "delayed initiation" of COC when/if bleeding concerns develop. Patients will be followed for 12 months.

Conditions

  • Contraception

Interventions

DRUG

150 mcg levonorgestrel/30 mcg ethinyl estradiol

concurrent use of COC with Nexplanon

Sponsors & Collaborators

  • Organon

    collaborator INDUSTRY

  • University of Arizona

    lead OTHER

Eligibility

Min Age
14 Years
Max Age
24 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-12-01
Primary Completion
2023-12-01
Completion
2024-12-01
FDA Drug
Yes

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05116371 on ClinicalTrials.gov